Core Points - Kanghui Pharmaceutical (603139) announced a change in its official email address to ir@sxkh.com due to actual work needs [1]

证券代码：603139 证券简称：康惠制药 公告编号：2025-058 陕西康惠制药股份有限公司 关于变更公司电子邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 变更前的公司电子邮箱：irsxkh@163.com 变更后的公司电子邮箱：ir@sxkh.com 除上述变更外，公司办公地址、联系电话等其他联系方式保持不变。变更后 的电子邮箱自本公告披露之日起正式启用，原邮箱地址同步停用，敬请广大投资 者注意。由此给投资者带来的不便，敬请谅解。欢迎广大投资者通过新的电子邮 箱与公司沟通交流。 特此公告。 陕西康惠制药股份有限公司董事会 2025 年 9 月 10 日 1 陕西康惠制药股份有限公司（以下简称"公司"）根据实际工作需要，对公 司电子邮箱进行变更，具体情况如下： ...

Core Viewpoint - The company, Kanghui Pharmaceutical, has undergone a change in control and has decided to halt the production of its subsidiary, Shaanxi Youbang, which has been characterized by heavy assets, low output, and significant losses [2][3]. Group 1: Control Change and Immediate Actions - Kanghui Pharmaceutical announced the formal takeover by Li Hongming and Wang Xuefang, with Yuehe Zhichuang becoming the new controlling shareholder [2]. - The previous controlling shareholder, Kanghui Holdings, voluntarily relinquished its voting rights on 10% of its shares [2]. - The decision to stop production at Shaanxi Youbang was made after failed attempts to improve profitability through product restructuring [2][3]. Group 2: Acquisition Background and Financial Performance - The acquisition of Shaanxi Youbang in 2020 was controversial due to the target company's prior production halts and ongoing losses, totaling nearly 15 million yuan from 2018 to 2020 [3]. - The acquisition was made at a 161% premium, with expectations of future profitability that were not met, leading to significant losses in subsequent years [3][4]. - From 2021 to 2023, Shaanxi Youbang accumulated losses of 73.64 million yuan, triggering a performance compensation clause of 269 million yuan [5][6]. Group 3: Operational Challenges and Future Outlook - Shaanxi Youbang faced operational difficulties, including management inefficiencies and production delays, which contributed to its inability to meet performance targets [4][6]. - The company attempted to adjust its product structure and improve operations but failed to achieve effective production, leading to continued financial losses [6][7]. - As of mid-2025, Shaanxi Youbang reported total assets of 324 million yuan and liabilities of 440 million yuan, indicating a severe financial distress situation [7]. Group 4: Strategic Shift and New Directions - Following the control change, Kanghui Pharmaceutical is focusing on reducing financial burdens by divesting from loss-making assets like Shaanxi Youbang [10]. - The new management is exploring opportunities in artificial intelligence, indicating a strategic pivot away from traditional pharmaceutical operations [10]. - The company has registered a new subsidiary in Beijing to develop AI-related software, reflecting its intent to integrate AI with its pharmaceutical business [10].

Core Viewpoint - The control change of Kanghui Pharmaceutical has been completed, with the major shareholder shifting from Kanghui Holdings to Yuehe Zhichuang, and the actual controllers changing to Li Hongming and Wang Xuefang. This transition comes amid the announcement of the shutdown of its loss-making subsidiary, Shaanxi Youbang [1][3]. Company Overview - Kanghui Pharmaceutical specializes in the research, production, and sales of traditional Chinese medicine. The change of control began in March 2023 when Kanghui Holdings transferred 22% of its shares to Yuehe Zhichuang for 543 million yuan, relinquishing voting rights for an additional 10% [1][3]. - Following the control change, Li Hongming was appointed as the chairman of the board, with other new appointments including Wang Xiuying and Ma Wenjun, indicating a significant shift in the management team [3]. Financial Performance - Shaanxi Youbang, a subsidiary of Kanghui Pharmaceutical, has been facing continuous losses, leading to its recent shutdown. In 2024 and the first half of 2025, Shaanxi Youbang reported revenues of 7.96 million yuan and 18.30 million yuan, respectively, with net losses of 52.51 million yuan and 23.67 million yuan [5][6]. - The impact of Shaanxi Youbang's losses on Kanghui Pharmaceutical's net profit was significant, with a reduction of 26.78 million yuan in 2024, accounting for 29.88% of the company's net profit [5]. Market Reaction - Following the announcement of the control change, Kanghui Pharmaceutical's stock price initially fell but later recovered slightly, closing at 23.23 yuan per share, down 0.94%, with a market capitalization of 2.32 billion yuan [1][5]. Strategic Implications - There are speculations that the new management may aim to leverage Kanghui Pharmaceutical as a vehicle for listing assets from their other company, Yian Tianxia, which is currently in the process of listing on the Beijing Stock Exchange [4][5]. - The company has a history of high-priced acquisitions that have not yielded expected results, raising questions about the effectiveness of the new management in turning around the company's fortunes [6][10].

Group 1 - The company announced the approval of multiple resolutions during the first meeting of the sixth board of directors, including the appointment of a securities affairs representative [2]

（文章来源：证券日报） 证券日报网讯 9月4日晚间，康惠制药发布公告称，公司2025年第二次临时股东大会于2025年9月4日召 开，审议通过了《关于取消公司监事会并修订的议案》等多项议案。 ...

二、公司控制权变更完成情况 公司于 2025 年 9 月 4 日召开 2025 年第二次临时股东大会，审议通过选举第 六届董事会非独立董事及独立董事的议案，第六届董事会已组建完成；同日，第 六届董事会召开了第一次会议，选举公司董事长、董事会下设各委员会委员并聘 任公司总经理、财务总监及董事会秘书等高级管理人员（具体内容详见公司于 2025 年 9 月 5 日在上海证券交易所网站披露的《2025 年第二次临时股东大会决 议公告》（公告编号：2025-054）及《第六届董事会第一次会议决议公告》（公告 编号：2025-055）。 证券代码：603139 证券简称：康惠制药 公告编号：2025-056 陕西康惠制药股份有限公司 关于公司控制权变更完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、公司控制权变更基本情况 2025 年 3 月 20 日, 陕西康惠制药股份有限公司（以下简称"康惠制药"、"上 市公司"）控股股东陕西康惠控股有限公司（以下简称"康惠控股"）与嘉兴悦合 智创科技合伙企业（有限合伙）（以下简称"悦 ...

Core Viewpoint - Kanghui Pharmaceutical announced the suspension of production at its subsidiary Shaanxi Youbang Biopharmaceutical Technology Co., Ltd. to reduce losses and protect shareholder interests [1][2] Group 1: Production Suspension - Shaanxi Youbang has suspended production in workshops 1, 2, and 3 due to ongoing losses and challenges in product adjustments and production processes [1] - The decision to suspend production aligns with the company's strategic direction to lower operational costs and mitigate further financial losses [1] Group 2: Financial Impact - In 2024, Shaanxi Youbang's total assets accounted for 16.91% of the company's latest audited total assets, while its revenue represented 1.42% of the consolidated revenue [2] - The net profit for Shaanxi Youbang in 2024 is projected to be -52.51 million, impacting the company's net profit attributable to shareholders by -26.78 million, which is 29.88% of the total [2] Group 3: Future Plans - The company will decide on the resumption of production based on market conditions and is actively seeking collaboration opportunities to maximize the asset value of Shaanxi Youbang [2]

Group 1: Equity Fund Market - The issuance of equity funds has seen a significant recovery, with 26 new funds established in just four days, totaling 175.87 billion yuan. Including an upcoming fund, the total issuance for the month has reached 226 billion yuan [1] Group 2: Special Bonds and Real Estate - As of September 3, 2023, 537 special bond storage projects have been implemented nationwide, with a total usage scale of 1,466 billion yuan aimed at supporting the acquisition of idle land and existing residential properties. However, only 18 projects are focused on acquiring existing properties, accounting for less than 4% [1] Group 3: AI/AR Glasses Market - In the first half of 2025, the sales volume of consumer-grade AI/AR glasses in China reached 262,000 units, marking a 73% year-on-year increase. The market is projected to reach 900,000 units by mid-2025, representing a staggering 133% growth [2] Group 4: Logistics and Warehousing - The Chinese warehousing index for August stood at 49.3%, a decrease of 0.8 percentage points from the previous month. The new order index for steel warehousing has seen a significant decline due to seasonal market effects [2] Group 5: OpenAI and AI Chip Production - OpenAI plans to collaborate with Broadcom to initiate large-scale production of its own AI chips starting next year [2] Group 6: Google Penalty - Google has been fined 325 million euros by the French National Commission for Information and Liberty for violating local laws by embedding ads in its Gmail service without user consent [3] Group 7: Citibank's UnionPay Membership Termination - China UnionPay has terminated Citibank's membership, reducing the number of foreign banks with UnionPay membership in China from nine to eight [3] Group 8: Store Expansion of Hu Shang Ayi - Hu Shang Ayi has only added 260 new stores in the first half of the year, falling short of its ambitious goal of 10,000 stores, while competitors like Gu Ming and Mi Xue have significantly outpaced its growth [4] Group 9: Zhang Liang's Shareholding Change - Zhang Liang has exited as a direct shareholder of Zhang Liang Spicy Hot Pot, indicating potential strategic adjustments within the company [4] Group 10: Xi Zhi Technology Financing - Xi Zhi Technology has completed a C-round financing exceeding 1.5 billion yuan, with participation from notable investors including Tencent [5] Group 11: Wuhan Holdings Acquisition - Wuhan Holdings plans to acquire 100% of Wuhan Municipal Institute for 1.6 billion yuan, which will enhance its business operations in engineering and consulting [6] Group 12: ST Tianmao Delisting - ST Tianmao intends to voluntarily withdraw its A-share listing and transfer to the delisting board, pending approval from the Shenzhen Stock Exchange [7] Group 13: Kanghui Pharmaceutical Production Halt - Kanghui Pharmaceutical's subsidiary, Shaanxi Youbang, has ceased production due to intensified market competition and declining sales margins [9] Group 14: Tax Payment by Langzi Co. - Langzi Co. has been ordered to pay 22.27 million yuan in back taxes, including income and value-added taxes, following a tax audit [10] Group 15: US Stock Market Performance - The US stock market saw all three major indices close higher, with the S&P 500 reaching a new high, driven by expectations of interest rate cuts [11] Group 16: Oil Price Decline - WTI crude oil prices have fallen below $64 amid ongoing rumors of OPEC+ production increases [12]

上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2025-2031年中国医药制造行业市场发展态势及前景战略研判报告》 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 2025年1-7月，医药制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从2011年起，规模 以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为9807个， 和上年同期相比，增加了142个，同比增长1.47%，占工业总企业的比重为1.88%。。 2016-2025年1-7月医药制造业企业数统计图 数据来 ...